Targeting MUC1 as a Marker for Myeloid Leukemia Stem Cells by DC/AML Fusions.

Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Donald Küfe(Dana-Farber Cancer Institute), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Zekui Wu(Dana-Farber Cancer Institute), Kenneth Miller(Sinai Hospital), Corrine Lenahan(Beth Israel Deaconess Medical Center), Adam Bissonnette(Dana-Farber Cancer Institute), James D. Levine(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center)
Blood
November 16, 2007
10.1182/blood.v110.11.1794.1794
Cited by 0

Related Papers

Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
|The Lancet|2021|1.7k
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
|Blood|2017|1.5k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k